• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Humoral Response in SARS-CoV-2 Convalescent Compared to Vaccinated Kidney Transplant Patients.

作者信息

Schimpf Judith, Sprenger-Mähr Hannelore, Davidovic Tamara, Lhotta Karl, Zitt Emanuel

机构信息

Department of Internal Medicine 3 (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, Austria.

Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.

出版信息

Transpl Int. 2022 Jan 18;35:10060. doi: 10.3389/ti.2021.10060. eCollection 2021.

DOI:10.3389/ti.2021.10060
PMID:35185362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8842381/
Abstract
摘要

相似文献

1
Humoral Response in SARS-CoV-2 Convalescent Compared to Vaccinated Kidney Transplant Patients.与接种疫苗的肾移植患者相比，新冠康复者的体液免疫反应
Transpl Int. 2022 Jan 18;35:10060. doi: 10.3389/ti.2021.10060. eCollection 2021.
2
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.接种 COVID-19 mRNA 疫苗后，需要数天才能诱导针对 SARS-CoV-2 的高特异性体液和细胞反应。
Front Immunol. 2021 Oct 4;12:726960. doi: 10.3389/fimmu.2021.726960. eCollection 2021.
3
A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse.第三剂疫苗可显著提高原发性体液无反应的肾移植受者的体液和细胞新冠病毒免疫力。
Kidney Int. 2021 Nov;100(5):1135-1136. doi: 10.1016/j.kint.2021.09.001. Epub 2021 Sep 9.
4
Early riser specific immune cell response by delayed-type hypersensitivity in a kidney transplant patient vaccinated against COVID-19.新冠疫苗接种后，一位早起的肾移植患者出现迟发型超敏反应的特定免疫细胞反应。
BMJ Case Rep. 2022 Dec 13;15(12):e250509. doi: 10.1136/bcr-2022-250509.
5
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.COVID-19 恢复期多发性硬化症患者对 SARS-CoV-2 的体液和细胞反应。
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2). doi: 10.1212/NXI.0000000000001143. Print 2022 Mar.
6
Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.肾移植患者接种 SARS-CoV-2 疫苗后的免疫反应。
Medicina (Kaunas). 2021 Dec 3;57(12):1327. doi: 10.3390/medicina57121327.
7
Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies.恢复期和接种疫苗的 COVID-19 多发性硬化症患者的体液和细胞免疫：疾病修正疗法的影响。
Mult Scler Relat Disord. 2022 Mar;59:103682. doi: 10.1016/j.msard.2022.103682. Epub 2022 Feb 8.
8
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.比较 BNT162b2 mRNA 疫苗接种者的恢复期和未接种者的 SARS-CoV-2 抗刺突蛋白 RBD IgG 和中和抗体与 COVID-19 患者的动力学。
BMC Med. 2021 Aug 23;19(1):208. doi: 10.1186/s12916-021-02090-6.
9
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
10
Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.评估 SARS-CoV-2 免疫在康复期儿童和青少年中的作用。
Front Immunol. 2021 Dec 17;12:797919. doi: 10.3389/fimmu.2021.797919. eCollection 2021.

引用本文的文献

1
SARS-CoV-2 vaccine-elicited immune responses in solid organ transplant recipients.实体器官移植受者中SARS-CoV-2疫苗引发的免疫反应。
Clin Transplant Res. 2024 Dec 31;38(4):247-256. doi: 10.4285/ctr.24.0062.
2
Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients.在接受mRNA疫苗初免的肾移植受者中，第三剂异源载体疫苗Ad26.COVS1接种后SARS-CoV-2抗体反应增强。
Transpl Int. 2022 Mar 22;36:10357. doi: 10.3389/ti.2022.10357. eCollection 2022.

本文引用的文献

1
A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse.第三剂疫苗可显著提高原发性体液无反应的肾移植受者的体液和细胞新冠病毒免疫力。
Kidney Int. 2021 Nov;100(5):1135-1136. doi: 10.1016/j.kint.2021.09.001. Epub 2021 Sep 9.
2
A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response.肾移植受者第三次注射BNT162b2 mRNA新冠疫苗可改善体液免疫反应。
Kidney Int. 2021 Nov;100(5):1132-1135. doi: 10.1016/j.kint.2021.08.017. Epub 2021 Aug 30.
3
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.肾移植受者对两剂mRNA-1273 SARS-CoV-2疫苗血清学反应微弱，接种第三剂后的抗体反应
JAMA. 2021 Jul 23;326(11):1063-5. doi: 10.1001/jama.2021.12339.
4
Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients.与初免-加强接种BNT162b2疫苗的透析患者相比，新冠康复者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）参考毒株、α和β变异株具有更强的细胞免疫和体液免疫。
Kidney Int. 2021 Sep;100(3):698-700. doi: 10.1016/j.kint.2021.07.006. Epub 2021 Jul 14.
5
Humoral response to SARS-CoV-2 is well preserved and symptom dependent in kidney transplant recipients.肾移植受者对 SARS-CoV-2 的体液免疫反应良好，且与症状相关。
Am J Transplant. 2021 Dec;21(12):3926-3935. doi: 10.1111/ajt.16746. Epub 2021 Jul 19.
6
COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination.实体器官移植受者接种SARS-CoV-2疫苗后感染新冠病毒
Am J Transplant. 2021 Oct;21(10):3496-3499. doi: 10.1111/ajt.16618. Epub 2021 May 18.
7
Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine.接受2剂mRNA-1273新型冠状病毒疫苗的肾移植受者中免疫接种率较低。
Kidney Int. 2021 Jun;99(6):1498-1500. doi: 10.1016/j.kint.2021.04.005. Epub 2021 Apr 20.
8
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.欧洲透析患者和肾移植受者的 ERA-EDTA 注册中心研究结果表明，他们因 COVID-19 导致的死亡率很高。
Kidney Int. 2020 Dec;98(6):1540-1548. doi: 10.1016/j.kint.2020.09.006. Epub 2020 Oct 15.